

가

8) Dexamethasone(Dexamethasone®, 5 mg/ml,) 0.3~0.4 cc

45 가 40

9) Parnes 10) 13 4 가 2

53%

38~72% 가 가

11-13) 가 1, 4 가 가

4 4 8

14)15) 가 8 가

가 500, 1000, 2000, 3000 Hz

가 10 dB

2000 3 2004 1 가 15%

1 Siegel's criteria

66 가

33 (34) 가

(), 33 가

().

66 10 independent t - test, paired

t - test, chi - square test , p 0.05

가

Solondo®(Prednisolone, () 60 mg/d 5 , 40 mg/d 2 , 20 mg/d 2 , 10 mg/d 1 10 , Tana-min®(Ginkgo biloba Ext., ())

Vacrax®(Acyclovir, ()) 66

Dichlozid(Hydrochlorothiazide, 33 (34) 39.3 , 42.8 .

())

Xylocaine® 10% pump spray(lidocaine 10 mg/dose, Astrazeneca) 13 : 20, 14 : 19 , 5.2 , 6.5 , 72.0 dB, 76.5 dB .

10 (p=0.096), (p=0.977), (p=0.831) (p=0.221)

. 25 - ga- (Table 1).

uge 1 cc

Table 1. Comparison of the characteristics between the patients treated with intratympanic steroid injection (ITSI) and control group

	ITSI group*	Control group	P value
Number	33 (34 ears)	33	
Age (years)	39.3	42.8	0.096
Sex (M : F)	13 : 20	14 : 19	0.977
Duration from onset to Tx (days)	5.2	6.5	0.831
PTA (dB)	72.0	76.5	0.221

*patients who were treated with a course of ITSI therapy, M : male, F : female, Tx : treatment, PTA : pure tone averages

Table 2. Hearing improvement in the patients treated with intratympanic steroid injection (ITSI) according to the response at initial treatment including oral steroids

	>20 dB HG	20 - 10 dB HG	No gain
Partial response* (n=16)	1 (6.3%)	6 (37.5%)	9 (56.3%)
No response (n=18)	4 (22.2%)	2 (11.1%)	12 (66.7%)

*patients who showed hearing improvement of more than 10 dB at initial treatment including oral steroids, were treated with a course of ITSI therapy, HG : hearing gain




Fig. 1. Comparison of hearing improvement* between intratympanic steroid injection group and control group. *hearing improvement : over than 10 dB in pure tone average (0.5, 1, 2, 3 KHz), ITSI : intratympanic steroid injection.

가 10 dB, 34, 13

38.2%(33, 13, 39.4%), 21, 가 2, 6.1%, 29 (87.8%), 가, 2 (6.1%) (Fig. 1).

가 72.0 dB, 4, 가 62.9 dB, 9.1 dB (p=0.001), (33.3%), 가 24%, 36.1%

((p=0.121)

가




Fig. 2. Comparison of hearing gain in PTA between intratympanic steroid injection group and control group. *comparison between PTA at 4 weeks and 8 weeks after onset of sudden sensorineural hearing loss (same interval to PTA follow up in the ITSI group), PTA : pure tone average, Before : PTA before ITSI therapy, After : PTA at 4 weeks after ITSI therapy.




Fig. 3. Hearing gain in intratympanic steroid injection group (34 ears). PTA : pure tone average (mean of 0.5, 1, 2, 3 KHz).

가 4 () 76.5 dB, 4, 74.1 dB, 2.4 dB, 가, 가 (p=0.463)(Fig. 2).

, 20 dB, 5, 10~20 dB, 8, 10 dB, 가 11 (Fig. 3).

10 dB, 가, (16) (18) Table 2, 가 7 (43.8%), 6 (p=0.127).

Table 3

Table 3. Hearing improvement in the patients treated with intratympanic steroid injection (ITSI) according to pure tone averages (PTA) before ITSI

	>20 dB HG	20 - 10 dB HG	No gain
26 - 40 dB (n=2)			2
41 - 55 dB (n=10)	2	1	7
56 - 70 dB (n=3)			3
71 - 90 dB (n=11)	1	6	4
90 - 110 dB (n=8)	2	1	5

HG : hearing gain

Table 4. Comparison of two groups according to responsiveness of intratympanic steroid injection

	Responsive group	Non-responsive group	P value
Number	13	21	
Age (years)	41.5	37.7	0.501
Sex (M : F)	2 : 10	10 : 11	
Duration from onset to initial Tx (days)	6.5	4.67	0.367
Duration from onset to ITSI (days)	31.8	35.1	0.391
Initial PTA (dB)	90.6	82.1	0.305
PTA before ITSI (dB)	77.6	67.0	0.201
Hearing improvement of initial Tx (systemic steroid)	8/13 (61.5%)	9/21 (42.8%)	0.291
Audiogram type (n)	Ascend (3), descend (3), flat (6)	Ascend (6), descend (7), flat (8)	
Presence of vertigo	7/12 (58.4%)	7/21 (33.3%)	0.273

Responsive group ; patients who showed hearing improvement over than 10 dB in pure tone average with intratympanic steroid injection (ITSI) therapy. Non-responsive group ; patients who showed no hearing improvement with ITSI therapy. M : male, F : female, PTA : pure tone average, Tx : treatment, n : number

10 dB 가 (0.25, 0.5, 1 KHz) 34 17 (50.0%), (2, 3 KHz) 12 (35.3%), (4, 6, 8 KHz) 13 (38.2%) , 가 (Fig. 4).

1 가 12 (35.3%), 2 가 5 (14.7%), 3 가 4 (11.8%), 4 가 7 (20.6%) 2.2

가 10 dB 13 가 3 가 20 3 가 10 , 가




Fig. 4. Hearing gain* in different frequencies in intratympanic steroid injection group (34 ears). *hearing gain : over than 10 dB in pure tone average (0.5, 1, 2, 3 KHz).

가 3 31 3 13 () 20 () 41.5 , 37.7 , 2 : 10, 10 : 11 , 6.5 , 4.7 , 31.8 , 35.1 가 90.6 dB, 82.1 dB 77.6 dB, 67.0 dB 가 13 8 (61.5%), 21 9 (42.8%) 가 (Table 4).

돌발성난청 환자에 대한 고실내 스테로이드 주입술의 효과

가

3)4)

8)

4.2~17.2%

2.8%

2)13)

가

1)6)7)16) 1977 Mattox 6) 28

20 (71%)

88 63 (72%)

1980 Wilson 1) 10)

34 11 (32%)

33 20 (61%)

hydrocortisone, methylprednisolone, dex-

xamethasone 가

Chandrasekhar¹¹⁾ dexamethasone histamine

가 dexamethasone

thasone 가

Parnes 10) methylprednisolone

methylprednisolone hydrocor-

tisone

dexamethasone

가

1~2 DNA

17) type (glucocorticoid) type 가

(mineralocorticoid) 가

17) glucocorti- Panes 10) 13 53%

coid 가 Chandraseckhar 11) 11 8 (72.7%)

가 Park 13) 32 65.6%

가 cytokine 가 Silverstein 12)

Glucocorticoid 38%

53~72%

가

(). glu-

cocorticoid Na,K - ATPase type

18) Na, Gianoli 14) 23

K - ATPase 83% 가 Kopke 15) 9

18)

가

가

19) cyclic adnosine 3', 5' - monophosphate

가

14)20)

가

4

4

15)

REFERENCES

- 1) Wilson WR, Byl FM, Laird N. *The efficacy of steroids in the treatment of idiopathic sudden hearing loss. A double-blind clinical study. Arch Otolaryngol* 1980;106:772-6.
- 2) Fetterman BL, Saunders JE, Luxford WM. *Prognosis and treatment of sudden sensorineural hearing loss. Am J Otol* 1996;17:529-36.
- 3) Wilson WR, Veltri RW, Laird N. *Viral and epidemiologic studies of idiopathic sudden hearing loss. Otolaryngol Head Neck Surg* 1983; 91:653-8.
- 4) Gussen R. *Sudden deafness of vascular origin: A human temporal bone study. Ann Otol Rhinol Laryngol* 1976;85:94-100.
- 5) Choung YH, Lee SJ, Lee JW, Mo JY, Moon SK, Park K. *The comparison of hearing recovery of sudden deafness treated with different protocols. Korean J Audiol* 2003;7:24-31.
- 6) Mattox DE, Simmons FB. *Natural history of sudden sensorineural hearing loss. Ann Otol Rhinol Laryngol* 1977;86:463-80.
- 7) Moskowitz D, Lee KJ, Smith HW. *Steroid use in idiopathic sudden sensorineural hearing loss. Laryngoscope* 1984;94:646-6.
- 8) Chon KM, Goh EK, Lee IW, Cho KS. *Clinical observation of sudden deafness in children. Korean J Otolaryngol* 2002;45:456-61.
- 9) Spandow O, Anniko M, Hellstrom S. *Hydrocortisone applied to the round window niche causes electrophysiological dysfunction of the inner ear. ORL J Otorhinolaryngol Spec* 1989;51:94-102.
- 10) Parnes LS, Sun AH, Freeman DJ. *Corticosteroid pharmacokinetics in the inner ear fluids: An animal study followed by clinical application. Laryngoscope* 1999;109:1-17.
- 11) Chandrasekhar SS. *Intratympanic dexamethasone for sudden sensorineural hearing loss: Clinical and laboratory evaluation. Otol Neurotol* 2001;22:18-23.
- 12) Silverstein H, Choo D, Rosenberg SI, Kuhn J, Seidman M, Stein I. *Intratympanic steroid treatment of inner ear disease and tinnitus. Ear Nose Throat J* 1996;75:468-76.
- 13) Park YS, Jeon EJ, Yeo SW, Park SN, Park JW, Kim KB. *The effect of intratympanic steroid injection for sudden sensorineural hearing loss. Korean J Otolaryngol* 2002;45:1136-40.
- 14) Gianoli GJ, Li JC. *Transtympanic steroids for treatment of sudden hearing loss. Otolaryngol Head Neck Surg* 2001;125:142-6.
- 15) Kopke RD, Hoffer ME, Wester D, O'Leary MJ, Jackson RL. *Targeted topical steroid therapy in sudden sensorineural hearing loss. Otol Neurotol* 2001;22:475-9.
- 16) Veldmann JE, Hanada T, Meeuwse F. *Diagnostic and therapeutic dilemmas in rapidly progressive sensorineural hearing loss and sudden deafness. Acta otolaryngol (Stock)* 1993;113:303-6.
- 17) Erichsen S, Bagger-Sjoberg D, Curtis L, Zuo J, Rarey KE, Hultcrantz M. *Appearance of glucocorticoid receptors in the inner ear of the mouse during development. Acta Otolaryngol (Stockh)* 1996;16:721-5.
- 18) Erichsen S, Zuo J, Curtis L, Rarey K, Hultcrantz M. *Na, K-ATPase α - and β -isoforms in the developing cochlea of the mouse. Hear Res* 1996;100:143-9.
- 19) Trune DR, Wobig RJ, Kempton JB, Hefeneider SH. *Steroid treatment improves cochlear function in the MRL. MpJ-Fas (lpr) autoimmune mouse. Hear Res* 1999;137:160-6.
- 20) Goodman HM. *Permissive effects of hormones on lypolysis. Endocrinol* 1970;86:1064-74.